Patterns of Care for Medicare Beneficiaries With Metastatic Prostate Cancer.
Christopher P FilsonThomas B RichardsDonatus U EkwuemeDavid H HowardPublished in: Urology practice (2024)
Most metastatic prostate cancer patients do not receive life-prolonging antineoplastic therapies. Improved adoption of effective cancer therapies when appropriate may increase length and quality of survival among metastatic prostate cancer patients.
Keyphrases
- prostate cancer
- squamous cell carcinoma
- small cell lung cancer
- radical prostatectomy
- end stage renal disease
- chronic kidney disease
- healthcare
- ejection fraction
- newly diagnosed
- quality improvement
- papillary thyroid
- prognostic factors
- affordable care act
- electronic health record
- lymph node metastasis
- free survival
- patient reported
- squamous cell
- health insurance
- childhood cancer